Word

ONCOBIOME

Status

Dead

Status Code

601

Status Date

Monday, October 2, 2017

Serial Number

86300247

Mark Type

4000

Filing Date

Wednesday, June 4, 2014

Abandoned Date

Thursday, September 21, 2017

Trademark Owner History

EVELO THERAPEUTICS, INC. - 1st New Owner Before Publication
VL28, Inc. - Original Applicant

Classifications

5 microbial preparations for pharmaceutical, veterinary and medical purposes, namely, microbial preparations for use as tumor suppressing agents, immuno-suppressing agents, immuno-stimulating agents, and anti-cancer agents; dietary supplements, nutritional supplements, nutraceuticals for use as dietary supplements, food supplements, nutritionally fortified vegetable-based food, beverages, and nutritional food bars, all of the foregoing containing microorganisms for medical, therapeutic, or preventative purposes; therapeutic pharmaceuticals containing microorganisms for medical and veterinary use for the treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers, and metastases; therapeutic pharmaceuticals containing derivatives of microorganisms for medical and veterinary use for the treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers, and metastases; pharmaceutical, veterinary and medical preparations and substances, namely, anti-microbial preparations and substances, anti-bacterial, anti-fungal, anti-viral, and anti-protist preparations and substances, all for the treatment of cancer, cancer symptoms, cancer-related diseases, and side-effects of cancer therapies; anti-cancer preparations and substances; preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals, namely, combination preparations containing in majority part antimicrobial preparations and lesser amounts of microbial preparations and anti-cancer preparations for use as a preservative; pharmaceutical preparations and substances for the treatment of cancer, namely, microbial and anti-microbial preparations for veterinary and medical use; anti-cancer preparations for use in treating cancer symptoms, cancer-related diseases, and side-effects of cancer therapies; pharmaceutical preparations for the treatment of infectious diseases and cancer, namely, combination preparations of anti-cancer agents, microbial preparations and anti-microbial preparations; diagnostic kits for diagnosing disease, determination of likelihood of disease, prognosis of responsiveness to therapy and/or patient prognosis comprised of diagnostic reagents and buffers for the detection of microbes, viral, bacterial, fungal, and parasitic or non-parasitic protist infections, inflammation, and biomarkers associated with pre-neoplastic lesions, neoplasms, tumors, cancers, or metastases; preparations for detecting mutations in genes for medical purposes as used in the collection of large-scale genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic medical data and related clinical data

9 scientific, analytical, and statistical computer software for creating and managing databases containing genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data derived from patient clinical care information and medical research data; computer software for analyzing and creating statistical models derived from patient clinical care information and medical research data in the nature of genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data

10 medical diagnostic instruments for screening, assessing, and determining appropriate courses of treatment in relation to pre-neoplastic lesions, neoplasms, tumors, cancers and metastases

42 electronic data storage services, namely, electronic storage of large-scale genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data and related clinical data for treatment and diagnostic purposes; database, computer-readable program and software development services, namely, development of scientific, analytical, and statistical software and related databases for use in conjunction with genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data gathered from patient clinical care information and medical research data; scientific, chemical, biochemical and microbiological research; scientific research in the field of genetics and genetic engineering of microbes; scientific research in the field of genetic and molecular tests, including tests for microbial populations in vertebrate samples; research and development of therapeutic pharmaceuticals, consumer medical products, diagnostic equipment and prognostic tools consisting of genetically engineered microorganisms, combinations of microorganisms, and individually selected microorganisms for treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers and metastases

44 medical clinics; veterinary dentistry; behavioural analysis for medical purposes; genetic testing for medical purposes; collection and preservation of human blood for medical purposes; medical diagnostic testing for assessing pre-neoplastic lesions, neoplasms, tumors, cancers, or metastases

Trademark Events

Oct 2, 2017

Abandonment Notice Mailed - Express Abandonment

Oct 2, 2017

Abandonment - Express Mailed

Sep 21, 2017

Exparte Appeal Terminated

Sep 21, 2017

Exparte Appeal Dismissed As Moot

Jul 21, 2017

Notification Of Action Denying Req For Recon E-Mailed

Jul 21, 2017

Action Denying Req For Recon E-Mailed

Jul 21, 2017

Action Continuing Final - Completed

Jul 3, 2017

Teas/Email Correspondence Entered

Jul 3, 2017

Correspondence Received In Law Office

Jun 29, 2017

Teas Request For Reconsideration Received

Jun 29, 2017

Ex Parte Appeal-Instituted

Jun 29, 2017

Jurisdiction Restored To Examining Attorney

Jun 29, 2017

Exparte Appeal Received At Ttab

Dec 29, 2016

Notification Of Final Refusal Emailed

Dec 29, 2016

Final Refusal E-Mailed

Dec 29, 2016

Final Refusal Written

Dec 6, 2016

Teas/Email Correspondence Entered

Dec 5, 2016

Correspondence Received In Law Office

Dec 5, 2016

Teas Response To Office Action Received

Jun 3, 2016

Notification Of Non-Final Action E-Mailed

Jun 3, 2016

Non-Final Action E-Mailed

Jun 3, 2016

Non-Final Action Written

May 13, 2016

Teas/Email Correspondence Entered

May 13, 2016

Correspondence Received In Law Office

May 13, 2016

Teas Response To Office Action Received

Nov 13, 2015

Notification Of Non-Final Action E-Mailed

Nov 13, 2015

Non-Final Action E-Mailed

Nov 13, 2015

Non-Final Action Written

Nov 4, 2015

Automatic Update Of Assignment Of Ownership

Oct 26, 2015

Applicant/Correspondence Changes (Non-Responsive) Entered

Oct 26, 2015

Teas Change Of Owner Address Received

Oct 23, 2015

Teas/Email Correspondence Entered

Oct 22, 2015

Correspondence Received In Law Office

Oct 22, 2015

Teas Response To Office Action Received

Apr 22, 2015

Notification Of Non-Final Action E-Mailed

Apr 22, 2015

Non-Final Action E-Mailed

Apr 22, 2015

Non-Final Action Written

Apr 1, 2015

Teas/Email Correspondence Entered

Apr 1, 2015

Correspondence Received In Law Office

Mar 30, 2015

Assigned To Lie

Mar 21, 2015

Teas Response To Office Action Received

Mar 2, 2015

Attorney/Dom.Rep.Revoked And/Or Appointed

Mar 2, 2015

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Sep 23, 2014

Notification Of Non-Final Action E-Mailed

Sep 23, 2014

Non-Final Action E-Mailed

Sep 23, 2014

Non-Final Action Written

Sep 16, 2014

Assigned To Examiner

Jun 19, 2014

New Application Office Supplied Data Entered In Tram